Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

AM Rx vs Meto

AM Rx
Graded #491

Lower grade

vs+12.399999999999999
Meto
Graded #281

Higher grade

The verdict

Meto takes it — 62/100 to 49.6/100.

Meto grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Meto is an insurance-accepting metabolic telehealth platform offering compounded semaglutide and compounded tirzepatide, prescribed after clinician-ordered lab work.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueAM Rx +5
50
45
Dose & formulationAM Rx +25
65
40
Clinical oversightMeto +47
41
88
Labs & monitoringMeto +36
49
85
FulfillmentMeto +9
58
67
Contract termsMeto +35
20
55
AM Rx · left barMeto · right bar

The numbers

MetricAM RxMeto
WeighScore49.6/10062/100
GradeCC
Scorecard rank#491#281
Semaglutide$151/mo (quarterly plan, plus a separate fee, compounded)Not disclosed
TirzepatideNot disclosedNot disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
AM Rx

Graded #491 · C

Strengths

  • Insurance coordination for brand-name GLP-1s — as low as $25/mo
  • All four major brand-name GLP-1s available (Ozempic, Wegovy, Zepbound, Mounjaro)
  • HSA and FSA accepted
  • Video visits available with providers averaging 10+ years' experience
  • Compounded semaglutide from $151/mo on the quarterly plan

Where it loses points

  • Active FTC/DOJ lawsuit over deceptive billing and subscription practices
  • Novo Nordisk false-advertising lawsuit (Aug 2025)
  • Parent company Zealthy holds a BBB D- rating with 2,370+ complaints
  • Trustpilot 2.0/5, with 85% one-star reviews citing billing disputes and unreachable support
  • FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Meto

Graded #281 · C

Strengths

  • Accepts major insurance (Blue Cross, Anthem, United, Aetna) — most patients pay $0–50 per visit
  • Requires lab work before prescribing GLP-1s; addresses root-cause metabolic drivers
  • Matches patients with endocrinologists and obesity medicine specialists within minutes
  • Offers compounded semaglutide and tirzepatide with board-certified physician oversight
  • Handles all prior-auth paperwork; provider location pages exist for all 50 US states

Where it loses points

  • Medication pricing fully gated behind quiz — no public cash price for sema or tirz
  • Lab panels are a separate out-of-pocket cost ($199–$399) unless covered by insurance
  • No LegitScript certification or named compounding pharmacy found on any public page
  • Company leadership and clinical team not disclosed publicly
  • Self-pay cash pricing exists per site copy but is not published anywhere

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard